Neural Stem Cells

Overview

Multipotent neural progenitors differentiated from UCT-WJ-MSCs; capable of differentiating into neurons, astrocytes, and oligodendrocytes with neurotrophic factor secretion

Related: Stem Cells Overview • Neural Exosomes

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Clinical potential

Akira Neural Stem Cells (NSCs) represent one of the most clinically significant differentiated products in the Akira portfolio. Generated from UCT-WJ-MSCs via neurosphere induction, these cells express the full NSC marker constellation and secrete a rich neurotrophic payload including BDNF, GDNF, NGF, CNTF, and VEGF. Their immune-privileged nature — inherited from the UCT-MSC parent — allows allogeneic use without immunosuppression, a critical advantage over ESC- or iPSC-derived neural cells (MHC matching is required to improve engraftment of iPSC-derived neurons in non-human primates, a requirement Akira NSCs are designed to avoid).^[2] NSCs home to sites of neural injury via chemokine gradients (SDF-1/CXCR4) and integrate into existing neural circuits, modulating neuroinflammation and activating endogenous repair mechanisms. Multiple preclinical models confirm migration toward injury, reduction of lesion size, improvement in behavioral outcomes, and increased expression of synaptic plasticity markers.^{[3] [4] [5]}

Mechanism of Action

Neurogenic Differentiation: Under CNS microenvironmental cues, Akira NSCs differentiate into the three primary neural lineages. Neurons (β-III Tubulin+, MAP2+) express functional voltage-gated ion channels, form synapses with host neurons, and integrate into neural circuits, with glutamatergic, GABAergic, and cholinergic subtypes emerging depending on the regional signaling environment. Astrocytes (GFAP+) support synapse formation and maintenance, regulate extracellular glutamate to prevent excitotoxicity, and contribute to BBB structural integrity. Oligodendrocytes (O4+, MBP+) produce myelin sheaths enabling saltatory conduction — critical in MS, SCI, and white matter disorders. Histological studies in SCI models confirm NSC-derived neurons extend axon projections and form synaptic contacts with host tissue within 4–12 weeks post-transplantation; functional and electrophysiological recovery from this circuit integration remains an active area of investigation.

Neurotrophic Factor Secretion: NSCs constitutively secrete BDNF (binds TrkB; activates PI3K/Akt survival and MAPK/ERK plasticity pathways — the most abundant NSC neurotrophic output), GDNF (binds RET/GFRα1;^[6] one of the most potent known survival factors for dopaminergic and motor neurons, critical in PD, ALS, and SMA — GDNF family members also directly reduce microglial activation via p38MAPK inhibition^[7]), NGF (binds TrkA; supports cholinergic neuron survival, relevant in Alzheimer's basal forebrain degeneration), NT-3/ NT-4 (support proprioceptive sensory neuron survival and cortical circuit maturation), and CNTF (protects motor neurons and photoreceptors from degeneration — relevant in ALS, SMA, and retinal dystrophies). VEGF adds a neurogenic effect beyond its angiogenic role, stimulating adult hippocampal neurogenesis for learning and memory circuit restoration.^{[8] [9]}

Neuroinflammation Resolution: NSCs reprogram CNS immune cells from pathological to repair phenotypes — a major, and likely underappreciated, driver of therapeutic benefit. NSC-secreted IL-10, TGF-β, and exosomal miR-146a suppress microglial M1 activation (NF-κB, iNOS, TNF-α, IL-1β) and promote the M2 repair phenotype. NSCs also reduce A1-reactive astrocyte conversion (C3+, GFAP+) — a neurotoxic phenotype linked to synapse loss and glutamate release, documented in AD and ALS and induced by activated microglia more broadly in CNS injury such as TBI.^[10] Exosomal cargo (miR-124, miR-21) suppresses NLRP3 inflammasome assembly in activated microglia, preventing caspase-1 activation and IL-1β/IL-18 release, while activating NRF2/HO-1 antioxidant pathways in neurons to reduce oxidative damage in TBI, stroke, and neurodegenerative states.

Blood-Brain Barrier Stabilization: NSC-secreted exosomes carrying miR-21, and potentially miR-124 and miR-132, upregulate tight junction proteins — occludin, claudin-5, and ZO-1 — in brain microvascular endothelial cells, reducing leakage of peripheral immune cells and inflammatory mediators into the CNS parenchyma. Exosomal miR-21a-5p has been shown to ameliorate blood-brain-barrier injury and hemorrhagic transformation,^[11] and exosomal miR-149 attenuates spinal-cord-injury-induced blood-spinal-cord barrier disruption via the ET-1/PI3K/Akt pathway.^[12] BBB integrity improvement is measurable within 48 hours of NSC delivery in ischemic stroke models.^[13]

Remyelination Support: Oligodendrocyte precursors derived from Akira NSCs migrate to demyelinated lesions, differentiate into mature oligodendrocytes, and ensheath exposed axons with new myelin. This has been demonstrated in EAE (experimental autoimmune encephalomyelitis) MS models with functional and neurophysiological recovery;^[14] effects in cuprizone demyelination models and precise conduction-velocity recovery timelines are less well characterized. Remyelination also protects neurons from DLK-mediated neurodegeneration and reduces the axonal degeneration that follows chronic demyelination due to loss of myelin's metabolic support.^[15]

Key Biomarkers & Molecular Cargo

Potential Applications

Neurodegenerative Diseases

• Alzheimer's Disease: neurotrophic support (BDNF/NGF for cholinergic basal forebrain neurons), amyloid clearance modulation, tau phosphorylation reduction via exosomal miRNA, neuroinflammation resolution, hippocampal neurogenesis for memory circuit reconstruction.
• Parkinson's Disease: dopaminergic circuit support via GDNF/BDNF secretion — best deployed alongside AB Dopamine Neurocytes, with NSCs providing the neurotrophic and anti-inflammatory environment that protects transplanted dopaminergic cells and surviving host neurons.
• ALS: motor neuron survival extension via GDNF (demonstrated in a rat model of familial ALS)^[16] and, by extrapolation from broader neurotrophic biology, BDNF/VEGF/CNTF; suppression of TDP-43 aggregation via autophagy-promoting exosomal cargo; microglial normalization.
• Huntington's Disease: striatal medium spiny neuron protection via BDNF supplementation (critically deficient in HD due to mHTT-mediated BDNF transport failure); neuroinflammation reduction.
• Multiple System Atrophy: oligodendrocyte support and alpha-synuclein aggregate clearance modulation in MSA-P and MSA-C phenotypes.

Acquired Neurologic Injury

• Traumatic Brain Injury (TBI): BBB stabilization, reduction of pericontusional lesion expansion, hippocampal dentate gyrus neurogenesis, synaptic plasticity restoration.
• Ischemic Stroke: peri-infarct neurogenesis, angiogenesis (VEGF), microglial M2 polarization, glutamate excitotoxicity reduction.
• Spinal Cord Injury (SCI): axonal sprouting and regeneration across the lesion site, oligodendrocyte-mediated remyelination, astrogliosis reduction, functional motor recovery.
• Hypoxic-Ischemic Encephalopathy (HIE): neonatal brain injury — NSC delivery reduces lesion volume and improves long-term neurodevelopmental outcomes in neonatal hypoxic-ischemia models.

Demyelinating & Autoimmune Neurologic

• Multiple Sclerosis: remyelination via oligodendrocyte differentiation, autoimmune T-cell suppression, BBB stabilization, BDNF-mediated axonal survival in demyelinated tracts.
• Neuromyelitis Optica (NMO): optic nerve and spinal cord lesion repair; mitigation of aquaporin-4 antibody-mediated damage through anti-inflammatory paracrine mechanisms.
• Transverse Myelitis: spinal cord inflammation resolution; axonal regeneration and remyelination support above and below the lesion level.

Neuropsychiatric & Neurodevelopmental

• Autism Spectrum Disorder: neuroinflammation modulation (microglial normalization), GABA/glutamate circuit balance restoration, hippocampal neurogenesis, gut-brain axis support.
• Treatment-Resistant Depression: hippocampal neurogenesis via BDNF-mediated CREB activation, normalization of HPA axis stress dysregulation, BDNF-TrkB pathway activation mimicking antidepressant mechanism of action.
• Cerebral Palsy: corticomotor pathway support, BDNF-mediated synaptic strength restoration, white matter repair in periventricular leukomalacia patterns.
• Epilepsy (Temporal Lobe / Refractory): GABAergic interneuron replacement — stem-cell-derived GABAergic interneurons functionally incorporate into the dentate gyrus in temporal lobe epilepsy models^[17] — hippocampal sclerosis mitigation, neuroinflammation suppression.

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

A 2019 study in Stem Cell Research & Therapy demonstrated that UCT-MSCs can be transdifferentiated into functional NSCs (neurospheres) within 12 hours using EGF bFGF. These MSC-derived neurospheres self-renewed, differentiated into neurons and glia, and showed significantly upregulated BDNF, GDNF, and VEGF secretion — a validated protocol underpinning Akira's NSC production.^[1]

A Phase I/IIa double-blind clinical trial (NEUROSTEM®, n=9 mild-to-moderate Alzheimer's disease patients) of intraventricular NSC administration via Ommaya reservoir into the right lateral ventricle demonstrated safety, signals of cognitive stabilization on K-MMSE and CDR over 36 months, and no dose-limiting toxicity at any dose level.

2024 research confirmed that hUC-MSC-derived exosomes attenuate neuroinflammation through the NRF2/NF-κB/NLRP3 pathway, reducing microglial activation and oxidative stress — with direct mechanistic relevance to NSC paracrine effects.^[18]

In spinal cord injury (SCI) rat contusion models, UCT-MSC-derived exosomes significantly suppressed NF-κB/MAPK signaling in microglia, improved BBB locomotor scores at 2, 4, and 8 weeks, and reduced apoptosis in the perilesional zone.^[19] Human iPSCs have also been shown to integrate, form synapses, and extend long axons after spinal cord injury.^[20]

In TBI rat models, NSC delivery reduced lesion volume by 30–45% at 4 weeks, elevated BDNF levels 2.8-fold, and improved cognitive function on Morris water maze testing.^[21]

A comprehensive review covering MSC and NSC-derived exosomes in Alzheimer's disease synthesized 88 publications (2014–2023) confirming consistent reduction of amyloid burden, tau phosphorylation, and microglial M1 activation across preclinical models.^[22]

In ischemic stroke models, human NSCs rapidly ameliorated symptomatic neuroinflammation within 48 hours of delivery.^[13] Delayed NSC administration after hypoxia-ischemia reduced sensorimotor deficits, cerebral lesion size, and neuroinflammation in neonatal mice, supporting the HIE application.^[23] In a chronic multiple sclerosis model, injection of adult neurospheres induced functional recovery.^[24]

Preclinical evidence for NSC benefit in ALS is directionally supportive (intrathecal delivery, ALSFRS-R stabilization signals) but is not yet tied to a single verifiable published source and should be treated as such rather than quantitatively definitive.